Technology
Health
Biotechnology

Rexahn Pharmaceuticals

$0.53
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.0159 (-2.91%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell RNN and other stocks, options, ETFs, and crypto commission-free!

About

Rexahn Pharmaceuticals, Inc., also called Rexahn Pharmaceuticals, is a clinical stage biopharmaceutical company, which engages in the research and development of oncology therapeutics. Its drug candidates include the following: RX-31171 for pancreatic, bladder, colon, and lung cancer; and RX-5902 for metastatic triple negative breast cancer. Read More The company was founded by Chang Ho Ahn on March 19, 2001 and is headquartered in Rockville, MD.

Employees
10
Headquarters
Rockville, Maryland
Founded
2001
Market Cap
20.49M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
414.45K
High Today
$0.5496
Low Today
$0.5212
Open Price
$0.54
Volume
86.92K
52 Week High
$2.38
52 Week Low
$0.50

Collections

Technology
Health
Biotechnology
Cancer Prevention
Medical
Biopharmaceutical
Research And Development
Therapy

News

Associated PressMar 8

Rexahn Pharmaceuticals Reports 2018 Financial Results

ROCKVILLE, Md., March 08, 2019 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE American: RNN), a clinical stage biopharmaceutical company developing innovative therapies to improve patient outcomes in cancers that are difficult to treat, today announced financial results for year ended December 31, 2018. 2018 and Recent Corporate Highlights: RX-3117 – Orally administered targeted nucleoside analogue -- Completed enrollment in the Phase 2a clinical trial of RX-3117 in combination with ABRAXANE® (pa...

880
Simply Wall StFeb 15

Is Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) A Volatile Stock?

Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! If you’re interested in Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN), then you might want to consider its beta (a measure of share price volatility) in order to understand how the stock could impact your portfolio. Volatility is considered to be a measure of risk in modern finance theory. Investors may think of volatility as falling into two main categories. First, we have company speci...

977

Earnings

-$0.21
-$0.13
-$0.04
$0.04
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
Actual
Expected May 3, Pre-Market
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.